title: A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service.
abstract: BACKGROUND
  Biological therapies have significantly improved the quality of life of patients with aggressive collagen vascular diseases. Blocking TNF activity may potentially confer a higher malignant potential for patients.
  
  
  OBJECTIVE
  To identify patients to whom anti-TNF therapies were recently prescribed and were referred to a multidisciplinary lung cancer service.
  
  
  METHODS
  Retrospective review of patients over an 18-month period who were referred to a multidisciplinary lung cancer service.
  
  
  RESULTS
  Three patients who underwent recent anti-TNF therapies and presented with solid organ tumours. All had significant additional risks for cancer including smoking and family history and active connective tissue diseases with a past history of immunosuppressive therapies.
  
  
  CONCLUSIONS
  Our series highlights the potential malignant risk of anti-TNF theraphy to a general medical audience.
authors.affiliation: Department of Respiratory Medicine, Education & Research Centre, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: O'Connell
authors.forename: M
authors.initials: M
authors.lastname: Hensey
authors.forename: A B
authors.initials: AB
authors.lastname: Mongey
authors.forename: D J
authors.initials: DJ
authors.lastname: Veale
authors.forename: S C
authors.initials: SC
authors.lastname: Donnelly
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D017809:Fatal Outcome; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced* / Q000556:secondary; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D012017:Referral and Consultation; D012189:Retrospective Studies; D000069283:Rituximab; D012509:Sarcoma / Q000139:chemically induced; D012907:Smoking / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000068879:Adalimumab; D008727:Methotrexate